WO2020013777A3 - Tablet formulations comprising metformin and sitagliptin - Google Patents
Tablet formulations comprising metformin and sitagliptinInfo
- Publication number
- WO2020013777A3 WO2020013777A3 PCT/TR2019/050190 TR2019050190W WO2020013777A3 WO 2020013777 A3 WO2020013777 A3 WO 2020013777A3 TR 2019050190 W TR2019050190 W TR 2019050190W WO 2020013777 A3 WO2020013777 A3 WO 2020013777A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sitagliptin
- metformin
- tablet formulations
- present
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a pharmaceutical tablet formulation comprising metformin and sitagliptin and at least one surfactant. Further the present invention provides a method for the preparation of said composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19834733.8A EP3784672A4 (en) | 2018-04-27 | 2019-03-25 | Tablet formulations comprising metformin and sitagliptin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201806019 | 2018-04-27 | ||
TR2018/06019 | 2018-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020013777A2 WO2020013777A2 (en) | 2020-01-16 |
WO2020013777A3 true WO2020013777A3 (en) | 2020-04-09 |
Family
ID=69141601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2019/050190 WO2020013777A2 (en) | 2018-04-27 | 2019-03-25 | Tablet formulations comprising metformin and sitagliptin |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3784672A4 (en) |
WO (1) | WO2020013777A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022074664A1 (en) * | 2020-10-05 | 2022-04-14 | V-Ensure Pharma Technologies Private Limited | An immediate release composition of sitagliptin hydrochloride |
KR20230009020A (en) * | 2021-07-08 | 2023-01-17 | 한미약품 주식회사 | A composite tablet containing sitagliptin, dapagliflozin and metformin |
CN114010612B (en) * | 2021-11-24 | 2022-06-28 | 上海普康药业有限公司 | Sitagliptin and metformin double-layer sustained release tablet and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
WO2013110085A1 (en) * | 2012-01-20 | 2013-07-25 | Handa Pharmaceuticals, Llc | Oral dosage forms for delivering metformin and sitagliptin |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY159203A (en) | 2007-07-19 | 2016-12-30 | Takeda Pharmaceuticals Co | Solid preparation comprising alogliptin and metformin hydrochloride |
WO2009111200A1 (en) * | 2008-03-04 | 2009-09-11 | Merck & Co., Inc. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
AR071175A1 (en) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO |
TR201722603A2 (en) * | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion |
-
2019
- 2019-03-25 EP EP19834733.8A patent/EP3784672A4/en active Pending
- 2019-03-25 WO PCT/TR2019/050190 patent/WO2020013777A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
WO2013110085A1 (en) * | 2012-01-20 | 2013-07-25 | Handa Pharmaceuticals, Llc | Oral dosage forms for delivering metformin and sitagliptin |
Also Published As
Publication number | Publication date |
---|---|
WO2020013777A2 (en) | 2020-01-16 |
EP3784672A2 (en) | 2021-03-03 |
EP3784672A4 (en) | 2022-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019120234A3 (en) | Compound functioning as bromodomain protein inhibitor, and composition | |
EP3914252A4 (en) | Pharmaceutical compositions of nilotinib | |
WO2020013777A3 (en) | Tablet formulations comprising metformin and sitagliptin | |
WO2016142708A3 (en) | Pharmaceutical composition | |
WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
WO2020138791A3 (en) | Sustained-release preparation comprising tofacitinib or pharmaceutically acceptable salt thereof and manufacturing method therefor | |
WO2019194773A3 (en) | The combination comprising linagliptin and metformin | |
MX2020010834A (en) | Solid formulation of insecticidal mixtures. | |
JOP20180071A1 (en) | CJ Healthcare Corporation | |
MX2022007707A (en) | Edoxaban tablets. | |
WO2019240699A3 (en) | Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion | |
WO2019203771A3 (en) | Solid oral pharmaceutical compositions comprising sitagliptin | |
EP3760195A4 (en) | Composition comprisng 2,3-butanediol as active ingredient | |
EP3539978A4 (en) | Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient | |
EP4166155A4 (en) | Composition comprising pentapeptide as active ingredient | |
WO2015119924A3 (en) | Fixed-dose combinations of antiviral compounds | |
WO2016005995A3 (en) | Glycol free stable liquid compositions of bendamustine | |
WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2016063289A3 (en) | Pharmaceutical tablet compositions comprising rifaximin | |
WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
WO2018069805A3 (en) | Method for preparation of liquid oral composition of l-thyroxin | |
WO2019098572A3 (en) | Pharmaceutical composition for alleviating liver fibrosis induced by hepatitis virus | |
WO2017222819A3 (en) | Solid state forms of ixazomib citrate | |
EP3626703A4 (en) | Novel compound and pharmaceutical composition comprising same as active ingredient | |
ZA202201888B (en) | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19834733 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019834733 Country of ref document: EP |